筛查结肠镜检出肿瘤的质量指标比较
该研究基于波兰结直肠癌筛查项目2000—2011年数据,纳入173,287例患者和262名内镜医师,评估腺瘤检出率(ADR)以外的结肠镜质量指标与结直肠癌(CRC)发病和死亡的关系。中位随访10年期间发现395例CRC,所有质量指标均与CRC风险及死亡显著相关,其中息肉检出率(PDR)和每次结肠镜腺瘤数(APC)与ADR相当,而进展期腺瘤检出率(AADR)预测能力显著低于ADR。
要点
- ADR≥24.9%者CRC风险低于ADR<12.1%者(HR 0.41,95%CI 0.25-0.66)。
- PDR≥42.7%者CRC风险低于PDR<19.9%者(HR 0.35,95%CI 0.24-0.51)。
- AADR是唯一预测能力显著低于ADR的质量指标(Harrell's C 59.7 vs 63.4,P=.001)。
核心结论
- 这项大型观察性研究证实ADR与CRC风险及死亡呈负相关,PDR和APC质量指标似乎与ADR相当。
研究设计与样本
- 研究使用波兰结直肠癌筛查项目2000—2011年收集的数据,为大型观察性研究。
- 纳入173,287例患者(中位年龄56岁,37.8%为男性)和262名内镜医师,医师均完成至少100例结肠镜检查。
- 计算腺瘤检出率(ADR)、息肉检出率(PDR)、进展期腺瘤检出率(AADR)、每次结肠镜腺瘤数(APC)和每次至少1枚腺瘤结肠镜的腺瘤数(APPC)。
- 随访至推荐监测前诊断CRC、死亡或2019年12月31日,中位随访10年、共1,490,683人年。
- 采用Cox比例风险模型估计风险比(HR)及95%置信区间(CI),用Harrell's C统计量比较各质量指标的预测能力。
主要发现
- 随访期间共识别395例CRC。
- 所有质量指标均与CRC风险和死亡显著相关。
- ADR≥24.9%者较ADR<12.1%者CRC风险降低(HR 0.41,95%CI 0.25-0.66)。
- PDR≥42.7%者较PDR<19.9%者CRC风险降低(HR 0.35,95%CI 0.24-0.51)。
- AADR≥9.1%者较AADR<4.1%者CRC风险降低(HR 0.69,95%CI 0.49-0.96);APC≥0.37者较APC<0.15者CRC风险降低(HR 0.35,95%CI 0.21-0.58);APPC≥1.54者较APPC<1.19者CRC风险降低(HR 0.54,95%CI 0.35-0.83)。
关键数值与推荐
- ADR≥24.9%对比<12.1%:CRC风险HR 0.41(95%CI 0.25-0.66)。
- PDR≥42.7%对比<19.9%:CRC风险HR 0.35(95%CI 0.24-0.51)。
- AADR≥9.1%对比<4.1%:CRC风险HR 0.69(95%CI 0.49-0.96)。
- APC≥0.37对比<0.15:CRC风险HR 0.35(95%CI 0.21-0.58)。
- APPC≥1.54对比<1.19:CRC风险HR 0.54(95%CI 0.35-0.83)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The proportion of colonoscopies with at least one adenoma (adenoma detection rate [ADR]) is inversely associated with colorectal cancer (CRC) risk and death. The aim of this study was to examine whether such associations exist for colonoscopy quality measures other than ADR. METHODS: We used data from the Polish Colorectal Cancer Screening Program collected in 2000-2011. For all endoscopists who performed ≥100 colonoscopies we calculated detection rates of adenomas (ADR), polyps (PDR), and advanced adenomas (≥10 mm/villous component/high-grade dysplasia [AADR]); and number of adenomas per colonoscopy (APC) and per colonoscopy with ≥1 adenoma (APPC). We followed patients until CRC diagnosed before recommended surveillance, death, or December 31, 2019. We estimated hazard ratios (HRs) and 95% confidence intervals (CIs) using Cox proportional-hazard models. We used Harrell's C statistic to compare the predictive power of the quality measures. RESULTS: Data on 173,287 patients (median age, 56 years; 37.8% male) and 262 endoscopists were used. During a median follow-up of 10 years and 1,490,683 person-years, we identified 395 CRCs. All quality measures were significantly associated with CRC risk and death. The relative reductions in CRC risk were as follows: for ADR ≥24.9% (reference <12.1%; HR, 0.41; 95% CI, 0.25-0.66), PDR ≥42.7% (reference <19.9%; HR, 0.35; 95% CI, 0.24-0.51), AADR ≥9.1% (reference <4.1%; HR, 0.69; 95% CI, 0.49-0.96), APC ≥0.37 (reference <0.15; HR, 0.35; 95% CI, 0.21-0.58), and APPC ≥1.54 (reference <1.19; HR, 0.54; 95% CI, 0.35-0.83). AADR was the only quality measure with significantly lower predictive power than ADR (Harrell's C, 59.7 vs 63.4; P = .001). Similar relative reductions were observed for CRC death. CONCLUSIONS: This large observational study confirmed the inverse association between ADR and CRC risk and death. The PDR and APC quality measures appear to be comparable with ADR.
引用
- Wieszczy P, Bugajski M, Januszewicz W, et al. Comparison of Quality Measures for Detection of Neoplasia at Screening Colonoscopy. Clin Gastroenterol Hepatol. 2022. PMID: 35341951. doi:10.1016/j.cgh.2022.03.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。